|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Dr. Paul Alexander Kasian Ph.D.||Exec. Chairman & CEO||N/D||N/D||1957|
|Dr. Jerzy Muchnicki||Exec. Director & Bus. Devel. Director||N/D||N/D||N/D|
|Mr. Paul Keith Mathieson Viney B. Bus, FCPA, FGIA, FCI||COO, CFO & Company Sec.||N/D||N/D||N/D|
Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage the women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. The company has a research and service agreement with The University of Melbourne for the development and enhancement of the BREVAGenplus breast cancer risk assessment test, as well as a strategic alliance with Blockchain Global Limited. Genetic Technologies Limited was founded in 1989 and is headquartered in Fitzroy, Australia.
L'ISS Governance QualityScore di Genetic Technologies Limited al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.